<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3694">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058822</url>
  </required_header>
  <id_info>
    <org_study_id>IM128-037</org_study_id>
    <nct_id>NCT03058822</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial</brief_title>
  <official_title>A Randomized, Open-label, Parallel-group, Single Subcutaneous Dose, Relative Bioavailability Study of the Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe (Process A) Compared to Drug in Vial (Process A) in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      A Phase 1, relative bioavailability study of BMS-931699 from prefilled syringe compared to
      drug in vial
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability of BMS-931699 following a single subcutaneous dose from prefilled syringe relative to drug in vial in healthy participants</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BMS-931699 following a single prefilled syringe or drug in vial subcutaneous dose in healthy participants by assessing adverse events and other physical assessments throughout study conduct</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Prefilled Syringe Upper Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prefilled Syringe Thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose from prefilled syringe into thigh of BMS-931699</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prefilled Syringe Abdomen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug in Vial Upper Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose from drug in vial into upper arm of BMS-931699</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug in Vial Thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose from drug in vial into thigh of BMS-931699</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug in Vial Abdomen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose from drug in vial into abdomen of BMS-931699</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-931699</intervention_name>
    <arm_group_label>Prefilled Syringe Upper Arm</arm_group_label>
    <arm_group_label>Prefilled Syringe Thigh</arm_group_label>
    <arm_group_label>Prefilled Syringe Abdomen</arm_group_label>
    <arm_group_label>Drug in Vial Upper Arm</arm_group_label>
    <arm_group_label>Drug in Vial Thigh</arm_group_label>
    <arm_group_label>Drug in Vial Abdomen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants as determined by no clinically significant deviation from normal
             in medical history, physical examination, electrocardiograms, and clinical laboratory
             determinations

          -  All participants must have hemoglobin, hematocrit, and platelets within normal limits
             at screening

          -  All participants must have activated partial thromboplastin time, prothrombin time,
             and international normalized ratio within normal limits at screening

        Exclusion Criteria:

          -  Any current or past history or risk for tuberculosis:

          -  Active tuberculosis requiring treatment within the previous 3 years. All participants
             will be required to have a QuantiFERON tuberculosis Gold or T-SPOT tuberculosis test
             performed at screening. Also excluded are participants with evidence of a past
             tuberculosis infection without documented adequate therapy. Participants with a
             positive QuantiFERON tuberculosis Gold or T-SPOT tuberculosis test at screening will
             not be eligible for the study. A QuantiFERON tuberculosis Gold or T-SPOT tuberculosis
             test performed within 4 weeks of dosing on Day 1 is acceptable as long as there is
             documentation of a negative result.

          -  Current clinical, radiographic, or laboratory evidence of active tuberculosis

          -  A history of herpes zoster
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>January 10, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
